Best Peptides for Testosterone Support: What the Research Shows
Written by NorthPeptide Research Team | Reviewed April 13, 2026
By NorthPeptide Research Team | April 13, 2026
No peptide directly replaces testosterone. But several research peptides act upstream in the HPG axis — stimulating the hypothalamic and pituitary signals that drive endogenous testosterone production. Gonadorelin acts at the pituitary to trigger LH and FSH release. Kisspeptin-10 acts even further upstream to stimulate GnRH. CJC-1295/Ipamorelin supports the GH axis, which intersects with androgen physiology. Follistatin inhibits myostatin and activin, affecting body composition through a parallel pathway. Each has a distinct mechanism and a distinct evidence base.
All peptides discussed here are sold strictly for laboratory research use. They are not intended for human administration, self-experimentation, or as treatments for testosterone deficiency or hypogonadism. This content is for educational purposes only. Always consult a licensed healthcare provider for medical concerns.
Understanding the HPG Axis
Testosterone production is governed by the hypothalamic-pituitary-gonadal (HPG) axis — a hierarchical hormonal cascade. The hypothalamus secretes gonadotropin-releasing hormone (GnRH) in a pulsatile pattern. GnRH reaches the anterior pituitary via the portal circulation and triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then acts on Leydig cells in the testes to drive testosterone synthesis. FSH acts on Sertoli cells to support spermatogenesis.
Upstream disruption at any level of this axis reduces testosterone output. Peptide research targeting testosterone support generally focuses on intervening at the hypothalamic or pituitary level — preserving or restoring the natural pulsatile signaling architecture rather than bypassing it with exogenous androgens.
Gonadorelin: The GnRH Analog
Gonadorelin is a synthetic decapeptide identical in sequence to endogenous GnRH (also known as LHRH). When administered in a pulsatile fashion, it binds GnRH receptors on pituitary gonadotroph cells and stimulates the release of both LH and FSH — the two gonadotropins that drive testicular function and testosterone synthesis.
Mechanism of Action
GnRH receptor binding activates a Gq/11-coupled signaling cascade, increasing intracellular calcium and activating protein kinase C, ultimately driving the exocytosis of LH and FSH granules. The pulsatile nature of administration is critical: continuous GnRH receptor stimulation causes receptor downregulation and paradoxically suppresses gonadotropin release (the principle behind GnRH agonist therapy for prostate cancer). Pulsatile delivery maintains receptor sensitivity and sustains LH/FSH output.[1]
Research Evidence
Gonadorelin has been extensively studied in clinical medicine for diagnosing HPG axis integrity (the GnRH stimulation test) and for restoring fertility in men with hypothalamic hypogonadism. In a landmark study, men with idiopathic hypogonadotropic hypogonadism achieved testosterone levels in the normal range following pulsatile GnRH delivery via programmable pump, with associated virilization and sperm production.[1]
In research settings, Gonadorelin serves as a standard tool for studying HPG axis responsiveness and for modeling conditions of GnRH deficiency or excess.
Kisspeptin-10: The Upstream Trigger
Kisspeptin-10 is a 10-amino acid fragment of the larger kisspeptin-54 molecule, the product of the KISS1 gene. Kisspeptins are endogenous neuropeptides that act on GPR54 (KISS1R) receptors, most critically on GnRH neurons in the hypothalamus. They represent the primary upstream driver of the HPG axis — essentially the “on switch” for GnRH pulsatility.
Mechanism of Action
Kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus integrate peripheral signals (including estrogen, testosterone, leptin, and metabolic status) and translate them into GnRH pulse regulation. Kisspeptin-10 administration in research settings triggers rapid, robust GnRH release, which subsequently drives LH and FSH pulses.[2]
Research Evidence
A pivotal human study by Dhillo et al. demonstrated that intravenous Kisspeptin-54 infusion in healthy men produced a dose-dependent increase in circulating LH, with downstream rises in testosterone confirming functional HPG axis engagement.[3] Subsequent studies confirmed that Kisspeptin-10, despite its shorter sequence, retains potent GPR54 agonist activity with a shorter half-life — making it a useful tool in pulsatile GnRH secretion research.
Kisspeptin-10 research has expanded to include female reproductive endocrinology, pubertal timing studies, and the investigation of conditions like hypothalamic amenorrhea and polycystic ovary syndrome — where upstream GnRH dysregulation is implicated.
CJC-1295 / Ipamorelin: The GH-Testosterone Axis
CJC-1295 and Ipamorelin are GH secretagogues that act on GHRH receptors and ghrelin receptors respectively, stimulating pulsatile growth hormone release from the anterior pituitary. While they do not directly stimulate testosterone synthesis, the GH/IGF-1 axis and the HPG axis are metabolically intertwined in several important ways.
The GH-Testosterone Connection
Growth hormone and IGF-1 support Leydig cell function and steroidogenic enzyme activity. Studies in GH-deficient men have shown that testosterone levels are often sub-optimal and improve with GH replacement therapy, suggesting cross-axis support.[4] Additionally, GH and IGF-1 improve body composition (reducing adipose tissue, increasing lean mass) — and adipose tissue is a site of aromatase enzyme activity that converts testosterone to estradiol. Reducing adiposity reduces aromatization, which can shift the testosterone-to-estradiol ratio favorably.
CJC-1295 Research Evidence
CJC-1295 (with DAC) was shown in Phase 2 human trials to produce sustained GH and IGF-1 elevation for up to 6 days following a single injection, with mean IGF-1 increases of 28-43% above baseline after multiple doses.[5]
Ipamorelin’s Profile
Ipamorelin is notable for its high selectivity — it stimulates GH release with minimal effect on cortisol, prolactin, or ACTH, which are undesirable off-target effects seen with less selective GH secretagogues like GHRP-6. This selectivity makes it a cleaner research tool for studying GH axis effects in isolation.[6]
Follistatin: The Myostatin Inhibition Angle
Follistatin is an endogenous glycoprotein that acts as a binding protein and inhibitor for several TGF-beta superfamily members — most notably activin and myostatin. Myostatin (GDF-8) is a negative regulator of skeletal muscle growth; animals and humans with myostatin loss-of-function mutations display dramatic muscle hypertrophy. Follistatin’s inhibition of myostatin removes this brake on muscle development.
Relation to Testosterone Research
Follistatin also binds and inhibits activin A and B — proteins that suppress FSH secretion at the pituitary level. By inhibiting activins, Follistatin can remove an inhibitory constraint on FSH release, potentially supporting gonadal function indirectly. This makes it a mechanistically interesting compound in male reproductive physiology research, though human clinical data specifically on this aspect remains limited compared to its muscle biology literature.
Research Evidence
In a gene therapy study, intramuscular injection of follistatin-encoding adeno-associated virus produced substantial and durable muscle mass increases in non-human primates — with no adverse effects observed at 15-month follow-up.[7] Research in patients with Becker and Duchenne muscular dystrophy has also explored follistatin as a therapeutic approach. Peptide-form follistatin (recombinant) is used as a research tool to study myostatin-inhibition pathways in vitro and in animal models.
Comparison Table: Peptides and Their HPG Relevance
| Peptide | Primary Target | Testosterone Mechanism | Evidence Level |
|---|---|---|---|
| Gonadorelin | Pituitary GnRH receptors | Direct: stimulates LH/FSH → testosterone | High (extensive human data) |
| Kisspeptin-10 | Hypothalamic GPR54 | Upstream: triggers GnRH → LH/FSH → testosterone | Moderate-High (human proof-of-concept trials) |
| CJC-1295 / Ipamorelin | GHRH receptor + ghrelin receptor | Indirect: GH/IGF-1 axis supports steroidogenesis; reduces aromatization via adiposity | Moderate (GH data strong; testosterone link indirect) |
| Follistatin | Activin / myostatin binding | Indirect: activin inhibition may support FSH; myostatin inhibition supports body composition | Emerging (animal + gene therapy data; limited peptide-specific human data) |
Why Not Direct Testosterone? The Research Rationale
Exogenous testosterone administration bypasses the entire HPG axis. Via negative feedback, it suppresses endogenous GnRH, LH, and FSH — shutting down intrinsic testicular function, impairing spermatogenesis, and causing testicular atrophy. Recovery after discontinuation can take months and is not guaranteed in all subjects.
Peptides that act upstream — at the hypothalamic or pituitary level — preserve the native feedback architecture. Gonadorelin and Kisspeptin-10 specifically are studied in clinical endocrinology for their ability to maintain HPG axis integrity while supporting gonadotropin output. This is a meaningfully different intervention category from testosterone replacement, and represents an active area of reproductive endocrinology research.
Research Considerations
- Pulsatility matters for Gonadorelin: Continuous infusion paradoxically suppresses LH/FSH (receptor desensitization). Research protocols model physiological pulsatile release patterns.
- Kisspeptin-10 half-life is short: Approximately 28 minutes for Kisspeptin-10 vs. several hours for Kisspeptin-54. This affects dosing interval design in research protocols.
- GH secretagogue synergy: CJC-1295 (GHRH analog) and Ipamorelin (ghrelin receptor agonist) act on different receptors and are typically studied in combination because their mechanisms are additive rather than redundant.
- Follistatin isoforms: Follistatin-288 and Follistatin-315 have different heparin-binding properties and tissue distributions. Research protocol design should specify the isoform studied.
Research-Grade Peptides, Independently Tested
All products verified for purity. Certificates of Analysis available on request.
Related Articles
References
- Crowley WF Jr, et al. The physiology of gonadotropin-releasing hormone (GnRH) secretion in men with GnRH deficiency. N Engl J Med. 1985;312(23):1473-1481. PubMed
- Gottsch ML, et al. A role for kisspeptins in the regulation of gonadotropin secretion in the mouse. Endocrinology. 2004;145(9):4073-4077. PubMed
- Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PubMed
- Carani C, et al. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med. 1997;337:91-95. PubMed
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PubMed
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PubMed
- Rodino-Klapac LR, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39(3):283-296. PubMed